Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Universidad Nacional Autonoma de Mexico | OTHER |
| National Polytechnic Institute, Mexico | OTHER |
Not provided
Not provided
Not provided
Not provided
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy. However, discontinuation of denosumab produces a rapid increase in bone turnover, bone loss and potentially increased risk of multiple vertebral fractures.
76 postmenopausal women from the climacteric clinic of the regional hospital "1o de Octubre" of the Institute of Security and Social Services for State Workers (ISSSTE) were firstly considered, of which 23 presented elimination criteria and only 55 who had received denosumab therapy for an average of 2.5 years without a significant improvement in hip and lumbar spine T-scores were enrolled. First, a general medical evaluation was performed. Serum levels of vitamin D were analysed to find the prevalence of hypovitaminosis D. A bone mineral density test was done to calculate hip and lumbar spine T-scores. Then, vitamin D was administrated daily for one year at a dose of 4,000 IU and the studies were repeated after one year. Statistical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. The arithmetic median (µ) and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables with Excel Word. Categorical variables were analysed with chi-squared or Fisher exact test depending on the number of participants in each cell. Normality was determined using the Shapiro-Wilk test. To compare two paired samples, the Wilcoxon signed-rank test was utilized. The assigned α value for this study was <0.05. In all cases, if a Montecarlo permutation was available, the exact p-value was taken instead of the raw p-value.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vitamin D 4000 IU | Experimental | 4000 IU of vitamin D were administrated once a day orally and calcium carbonate 1.2 g a day in a single dose. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cholecalciferol | Drug | 4000 IU were administrated once a day for 3 months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with hip T-score improvement at 12 months | It refers to the number of participants who improved their hip T-score at three months after treatment. | 12 months |
| Number of participants with lumbar spine T-score improvement at 12 months | It refers to the number of participants who improved their lumbar spine T-score at three months after treatment. | 12 months |
| Number of participants with osteoporosis of the hip at 12 months | It refers to the number of participants that present a hip T-score above -2.5 three months after treatment. | 12 months |
| Number of participants with osteoporosis of the lumbar spine at 12 months | It refers to the number of participants that present a lumbar spine T-score greater than -2.5 three months after treatment. | 12 months |
| Number of participants with osteopenia on the hip at 12 months | It refers to the number of participants that present a hip T-score from -1 to -2.4 three months after treatment. | 12 months |
| Number of participants with osteopenia of the lumbar spine at 12 months | It refers to the number of participants that present a lumbar spine T-score from -1 to -2.4 three months after treatment. | 12 months |
| Number of participants with normal hip T-score at 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with vitamin D sufficiency at 12 months | It refers to the number of participants who reached serum levels of vitamin D above 29 pg/ml after three months of treatment. | 12 months |
| Number of participants with vitamin D insufficiency at 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| María B Brito-Gavilanes, M.D. | Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1 ISSSTE | Principal Investigator |
| Patricia Loranca-Moreno, M.D., M.Sc. | Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE. | Principal Investigator |
| Juan M Ocampo-Godínez, M.D., P.hD | Laboratory of Tissue Engineering, UNAM | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Patricia Loranca-Moreno | Mexico City | Gustavo A. Madero | 07300 | Mexico |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28789921 | Background | Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5. | |
| 28144701 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014808 | Vitamin D Deficiency |
| D015663 | Osteoporosis, Postmenopausal |
| D010024 | Osteoporosis |
| D001851 | Bone Diseases, Metabolic |
| ID | Term |
|---|---|
| D001361 | Avitaminosis |
| D003677 | Deficiency Diseases |
| D044342 | Malnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D002762 | Cholecalciferol |
| ID | Term |
|---|---|
| D002782 | Cholestenes |
| D002776 | Cholestanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
76 participants were considered from the climacteric clinic of the regional hospital "1o de Octubre" of the Institute of Security and Social Services for State Workers (ISSSTE), of which 23 presented elimination criteria, and 55 were included in the study.
Not provided
Not provided
Not provided
Not provided
It refers to the number of participants that present a hip T-score below -1 three months after treatment.
| 12 months |
| Number of participants with normal lumbar spine T-score at 12 months | It refers to the number of participants that present a lumbar spine T-score below -1 three months after treatment. | 12 months |
| Number of participants with improvement in serum levels of vitamin D at 12 months | Improvement in serum levels of 25-hydroxy vitamin D [25(OH)D] was considered when serum vitamin D levels increased concerning baseline levels. | 12 months |
| Number of participants with clinical remission of hypovitaminosis D at 12 months | Remission of hypovitaminosis D was considered when serum levels of 25-hydroxy vitamin D [25(OH)D] were above 29 pg/ml. | 12 months |
It refers to the number of participants who reached serum levels of vitamin D of 21 to 29 pg/ml after three months of treatment. |
| 12 months |
| Number of participants with vitamin D deficiency at 12 months | It refers to the number of participants who reached serum levels of vitamin D less than 20 pg/ml after three months of treatment. | 12 months |
| McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017 May;28(5):1723-1732. doi: 10.1007/s00198-017-3919-1. Epub 2017 Jan 31. |
| 30324412 | Background | Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018-4704-5. Epub 2018 Oct 15. |
| 33141482 | Background | Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Atsumi T, Miyoshi H. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. J Diabetes Investig. 2021 Jul;12(7):1293-1300. doi: 10.1111/jdi.13458. Epub 2020 Dec 13. |
| 28892457 | Background | Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. |
| 19671655 | Background | Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. |
| 31036625 | Background | Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019 Jul;78(7):899-907. doi: 10.1136/annrheumdis-2018-214827. Epub 2019 Apr 29. |
| D009750 |
| Nutritional and Metabolic Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
| D011083 |
| Polycyclic Compounds |
| D013261 | Sterols |
| D014807 | Vitamin D |
| D012632 | Secosteroids |
| D008563 | Membrane Lipids |
| D008055 | Lipids |